Talk:AB-CHMINACA: Difference between revisions

{{proofread}}

'''AB-CHMINACA''' ('''N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide''') is a drug that acts as a potent agonist for the [[Psychoactive class::cannabinoid]] [[receptor]]s which produces subjective effects somewhat similar to that of [[cannabis]]. It was developed by Pfizer and disclosed in a 2009 patent<ref>(WO2009106980) INDAZOLE DERIVATIVES (Patentscope) | https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009106980</ref> as a potential [[analgesic]] medication, but was never pursued for human use. It was first found in US customs seizures in February 2014 as a shipment of a kilogram of the chemical originating from China, and detected in herbal blends from March 2014.<ref>Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration (December 2014). "N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone(THJ-2201) - Background Information and Evaluation of 'Three Factor Analysis' (Factors 4, 5, and 6) for Temporary Scheduling". | https://www.grassley.senate.gov/sites/default/files/news/upload/3-factor%20analysis%20AB-CHMINACA%20AB-PINACA%20THJ2201%2012172014.pdf</ref>